

# Irene Ferrer

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1612532/irene-ferrer-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26  
papers

960  
citations

15  
h-index

29  
g-index

29  
ext. papers

1,192  
ext. citations

6.4  
avg, IF

3.84  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 26 | Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 1551-66  | 3.5  | 318       |
| 25 | RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. <i>Cancer Research</i> , <b>2012</b> , 72, 2879-88                               | 10.1 | 142       |
| 24 | Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. <i>Human Pathology</i> , <b>2013</b> , 44, 1973-81   | 3.7  | 60        |
| 23 | Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , <b>2017</b> , 8, 1392-1407  | 8    | 53        |
| 22 | MicroRNA-dependent regulation of transcription in non-small cell lung cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e90524   | 4.7  | 53        |
| 21 | PPP1CA contributes to the senescence program induced by oncogenic Ras. <i>Carcinogenesis</i> , <b>2008</b> , 29, 491-9  | 4.6  | 51        |
| 20 | Characterization of the p53 response to oncogene-induced senescence. <i>PLoS ONE</i> , <b>2008</b> , 3, e3230   | 3.7  | 32        |
| 19 | Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. <i>PLoS ONE</i> , <b>2010</b> , 5, e9305   | 3.7  | 26        |
| 18 | Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. <i>Cell Cycle</i> , <b>2011</b> , 10, 2751-62  | 4.7  | 24        |
| 17 | The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. <i>Scientific Reports</i> , <b>2018</b> , 8, 2394  | 4.9  | 22        |
| 16 | The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma. <i>Human Pathology</i> , <b>2014</b> , 45, 942-51  | 3.7  | 19        |
| 15 | Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). <i>Oncotarget</i> , <b>2016</b> , 7, 67033-67046   | 3.9  | 19        |
| 14 | Stromal signatures in endometrioid endometrial carcinomas. <i>Modern Pathology</i> , <b>2014</b> , 27, 631-9  | 9.8  | 18        |
| 13 | Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. <i>Disease Markers</i> , <b>2016</b> , 2016, 2138627  | 3.2  | 18        |
| 12 | MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 195 | 12.8 | 16        |
| 11 | Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. <i>Journal of Pathology</i> , <b>2011</b> , 225, 73-82  | 9.4  | 15        |
| 10 | Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 612-624   | 15.9 | 12        |

|   |   |      |    |
|---|---|------|----|
| 9 | Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. <i>Disease Markers</i> , <b>2016</b> , 2016, 9214056   | 3.2  | 12 |
| 8 | Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 667-674.e1                              | 4.9  | 11 |
| 7 | Spinophilin loss contributes to tumorigenesis in vivo. <i>Cell Cycle</i> , <b>2011</b> , 10, 1948-55  | 4.7  | 10 |
| 6 | FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. <i>Lung Cancer</i> , <b>2019</b> , 131, 112-121                                       | 5.9  | 9  |
| 5 | FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. <i>EBioMedicine</i> , <b>2020</b> , 53, 102683                                     | 8.8  | 7  |
| 4 | A patent review of FGFR4 selective inhibition in cancer (2007-2018). <i>Expert Opinion on Therapeutic Patents</i> , <b>2019</b> , 29, 429-438   | 6.8  | 5  |
| 3 | Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 19945-19960  | 3.3  | 5  |
| 2 | Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1622-1623   | 21.7 | 2  |
| 1 | Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. <i>Cells</i> , <b>2019</b> , 8, | 7.9  | 1  |